Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention
Objective We investigated the efficacy and safety of liraglutide 3 mg daily in combination with diet and exercise 2, 4, and 6 months after initiation in real-world settings in Korea. Methods People first using liraglutide starting in 2018 were recruited from ten sites in Korea. Body weight and body...
Gespeichert in:
| Veröffentlicht in: | International Journal of Obesity 2021-04, Vol.45 (4), p.776-786 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 786 |
|---|---|
| container_issue | 4 |
| container_start_page | 776 |
| container_title | International Journal of Obesity |
| container_volume | 45 |
| creator | Park, Jung Ha Kim, Ju Young Choi, Jong Han Park, Hye Soon Shin, Hyun-Young Lee, Jae Min Kim, Jin-Wook Ko, Hae-Jin Chon, Suk Kim, Bu Kyung Kim, Chul Sik Lim, Soo |
| description | Objective
We investigated the efficacy and safety of liraglutide 3 mg daily in combination with diet and exercise 2, 4, and 6 months after initiation in real-world settings in Korea.
Methods
People first using liraglutide starting in 2018 were recruited from ten sites in Korea. Body weight and body mass index (BMI) were measured after 2, 4, and 6 months and compared with baseline values.
Results
The full cohort comprised 769 participants: 672 in the 2-month group, 427 in the 4-month group, and 219 in the 6-month group. The baseline mean ± standard deviation of BMI and body weight were 32.2 ± 5.1 kg/m
2
, and 87.5 ± 18.8 kg, respectively. Body weight and BMI decreased after initiation of liraglutide treatment: −2.94 kg and −1.08 kg/m
2
at 2 months; −4.23 kg and −1.55 kg/m
2
at 4 months, and −5.14 kg and −1.89 kg/m
2
at 6 months (all
P
|
| doi_str_mv | 10.1038/s41366-021-00739-z |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2479742887</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A656640502</galeid><sourcerecordid>A656640502</sourcerecordid><originalsourceid>FETCH-LOGICAL-c473t-fd2b44bdc295612b2761701570247ef3f5f36eb2859d1c0ee5aa290371c10ad73</originalsourceid><addsrcrecordid>eNp9kk1rFTEUhgdR7LX6B1xIQBA3U0-SSXJnWUr9gIIbXYfMzMm9KTNJTTKW21Vd-jf9JWZ6a7UikkUg5znv-chbVc8pHFHg6zepoVzKGhitARRv66sH1Yo2StaiadXDagUcVA1CioPqSUrnACAEsMfVAeeN4lTJVfXt1Frss_uKHlMiwZLRRbMZ5-wGJPzH9fdpQ2yIJG-R5IgmT-jzwoUOk8s74jwxpATG-jLEcSAJc3Z-Qy5d3oY5l3hGn0qBomwx5d2IN2-xlMwu-KfVI2vGhM9u78Pq89vTTyfv67OP7z6cHJ_Vfek113ZgXdN0Q89aISnrmJJUARUKWKPQcissl9ixtWgH2gOiMIa1wBXtKZhB8cPq9V73IoYvc2lETy71OI7GY5iTLjKtath6vaAv_0LPwxx96U4zAZJSIcvq76iNGVE7b0OOpl9E9bEUUjZQll2oo39Q5Qw4uT54tK6830t49UfCtiw2b1NYPiT4dB9ke7CPIaWIVl9EN5m40xT0YhC9N4guBtE3BtFXJenF7WhzN-Fwl_LLEQXgeyCVkN9g_D37f2R_AsMExrM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2506115641</pqid></control><display><type>article</type><title>Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention</title><source>MEDLINE</source><source>Springer Journals</source><source>Nature</source><creator>Park, Jung Ha ; Kim, Ju Young ; Choi, Jong Han ; Park, Hye Soon ; Shin, Hyun-Young ; Lee, Jae Min ; Kim, Jin-Wook ; Ko, Hae-Jin ; Chon, Suk ; Kim, Bu Kyung ; Kim, Chul Sik ; Lim, Soo</creator><creatorcontrib>Park, Jung Ha ; Kim, Ju Young ; Choi, Jong Han ; Park, Hye Soon ; Shin, Hyun-Young ; Lee, Jae Min ; Kim, Jin-Wook ; Ko, Hae-Jin ; Chon, Suk ; Kim, Bu Kyung ; Kim, Chul Sik ; Lim, Soo</creatorcontrib><description>Objective
We investigated the efficacy and safety of liraglutide 3 mg daily in combination with diet and exercise 2, 4, and 6 months after initiation in real-world settings in Korea.
Methods
People first using liraglutide starting in 2018 were recruited from ten sites in Korea. Body weight and body mass index (BMI) were measured after 2, 4, and 6 months and compared with baseline values.
Results
The full cohort comprised 769 participants: 672 in the 2-month group, 427 in the 4-month group, and 219 in the 6-month group. The baseline mean ± standard deviation of BMI and body weight were 32.2 ± 5.1 kg/m
2
, and 87.5 ± 18.8 kg, respectively. Body weight and BMI decreased after initiation of liraglutide treatment: −2.94 kg and −1.08 kg/m
2
at 2 months; −4.23 kg and −1.55 kg/m
2
at 4 months, and −5.14 kg and −1.89 kg/m
2
at 6 months (all
P
< 0.001). In the 6-month cohort, 52.5% and 18.3% of subjects lost ≥5% and ≥10% of body weight, respectively. After 6 months, systolic and diastolic blood pressure decreased significantly by 3.90 and 1.93 mmHg, respectively. In those with diabetes mellitus, HbA1c and fasting glucose levels decreased significantly by 1.14% and 27.8 mg/dl, respectively. Among all participants, 27.6% experienced adverse effects, including nausea (20.8%), vomiting (5.2%), diarrhoea (2.5%), and skin rash (3.6%). Documented reasons for discontinuation of treatment were lack of effect (4.4%), adverse events (4.3%), and high cost (3.1%).
Conclusions
In real-world settings in Korea, daily treatment with liraglutide 3 mg was associated with clinically meaningful weight loss without serious adverse events.</description><identifier>ISSN: 0307-0565</identifier><identifier>EISSN: 1476-5497</identifier><identifier>DOI: 10.1038/s41366-021-00739-z</identifier><identifier>PMID: 33473176</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/163/2743/393 ; 692/699/1702/393 ; 692/699/2743/2037 ; 692/699/2743/393 ; Adult ; Adverse events ; Antidiabetics ; Blood Pressure ; Body Mass Index ; Body size ; Body Weight ; Body weight loss ; Diabetes mellitus ; Diarrhea ; Drug therapy ; Epidemiology ; Exercise ; Female ; Health Promotion and Disease Prevention ; Heart Disease Risk Factors ; Humans ; Internal Medicine ; Life Style ; Liraglutide ; Liraglutide - therapeutic use ; Male ; Medicine ; Medicine & Public Health ; Metabolic Diseases ; Middle Aged ; Nausea ; Obesity ; Obesity - therapy ; Patient outcomes ; Public Health ; Republic of Korea ; Vomiting ; Weight Loss</subject><ispartof>International Journal of Obesity, 2021-04, Vol.45 (4), p.776-786</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Limited 2021</rights><rights>COPYRIGHT 2021 Nature Publishing Group</rights><rights>The Author(s), under exclusive licence to Springer Nature Limited 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c473t-fd2b44bdc295612b2761701570247ef3f5f36eb2859d1c0ee5aa290371c10ad73</citedby><cites>FETCH-LOGICAL-c473t-fd2b44bdc295612b2761701570247ef3f5f36eb2859d1c0ee5aa290371c10ad73</cites><orcidid>0000-0001-6018-3337 ; 0000-0002-4137-1671 ; 0000-0002-1269-333X ; 0000-0001-9584-0974</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41366-021-00739-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41366-021-00739-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33473176$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Park, Jung Ha</creatorcontrib><creatorcontrib>Kim, Ju Young</creatorcontrib><creatorcontrib>Choi, Jong Han</creatorcontrib><creatorcontrib>Park, Hye Soon</creatorcontrib><creatorcontrib>Shin, Hyun-Young</creatorcontrib><creatorcontrib>Lee, Jae Min</creatorcontrib><creatorcontrib>Kim, Jin-Wook</creatorcontrib><creatorcontrib>Ko, Hae-Jin</creatorcontrib><creatorcontrib>Chon, Suk</creatorcontrib><creatorcontrib>Kim, Bu Kyung</creatorcontrib><creatorcontrib>Kim, Chul Sik</creatorcontrib><creatorcontrib>Lim, Soo</creatorcontrib><title>Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention</title><title>International Journal of Obesity</title><addtitle>Int J Obes</addtitle><addtitle>Int J Obes (Lond)</addtitle><description>Objective
We investigated the efficacy and safety of liraglutide 3 mg daily in combination with diet and exercise 2, 4, and 6 months after initiation in real-world settings in Korea.
Methods
People first using liraglutide starting in 2018 were recruited from ten sites in Korea. Body weight and body mass index (BMI) were measured after 2, 4, and 6 months and compared with baseline values.
Results
The full cohort comprised 769 participants: 672 in the 2-month group, 427 in the 4-month group, and 219 in the 6-month group. The baseline mean ± standard deviation of BMI and body weight were 32.2 ± 5.1 kg/m
2
, and 87.5 ± 18.8 kg, respectively. Body weight and BMI decreased after initiation of liraglutide treatment: −2.94 kg and −1.08 kg/m
2
at 2 months; −4.23 kg and −1.55 kg/m
2
at 4 months, and −5.14 kg and −1.89 kg/m
2
at 6 months (all
P
< 0.001). In the 6-month cohort, 52.5% and 18.3% of subjects lost ≥5% and ≥10% of body weight, respectively. After 6 months, systolic and diastolic blood pressure decreased significantly by 3.90 and 1.93 mmHg, respectively. In those with diabetes mellitus, HbA1c and fasting glucose levels decreased significantly by 1.14% and 27.8 mg/dl, respectively. Among all participants, 27.6% experienced adverse effects, including nausea (20.8%), vomiting (5.2%), diarrhoea (2.5%), and skin rash (3.6%). Documented reasons for discontinuation of treatment were lack of effect (4.4%), adverse events (4.3%), and high cost (3.1%).
Conclusions
In real-world settings in Korea, daily treatment with liraglutide 3 mg was associated with clinically meaningful weight loss without serious adverse events.</description><subject>692/163/2743/393</subject><subject>692/699/1702/393</subject><subject>692/699/2743/2037</subject><subject>692/699/2743/393</subject><subject>Adult</subject><subject>Adverse events</subject><subject>Antidiabetics</subject><subject>Blood Pressure</subject><subject>Body Mass Index</subject><subject>Body size</subject><subject>Body Weight</subject><subject>Body weight loss</subject><subject>Diabetes mellitus</subject><subject>Diarrhea</subject><subject>Drug therapy</subject><subject>Epidemiology</subject><subject>Exercise</subject><subject>Female</subject><subject>Health Promotion and Disease Prevention</subject><subject>Heart Disease Risk Factors</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Life Style</subject><subject>Liraglutide</subject><subject>Liraglutide - therapeutic use</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolic Diseases</subject><subject>Middle Aged</subject><subject>Nausea</subject><subject>Obesity</subject><subject>Obesity - therapy</subject><subject>Patient outcomes</subject><subject>Public Health</subject><subject>Republic of Korea</subject><subject>Vomiting</subject><subject>Weight Loss</subject><issn>0307-0565</issn><issn>1476-5497</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kk1rFTEUhgdR7LX6B1xIQBA3U0-SSXJnWUr9gIIbXYfMzMm9KTNJTTKW21Vd-jf9JWZ6a7UikkUg5znv-chbVc8pHFHg6zepoVzKGhitARRv66sH1Yo2StaiadXDagUcVA1CioPqSUrnACAEsMfVAeeN4lTJVfXt1Frss_uKHlMiwZLRRbMZ5-wGJPzH9fdpQ2yIJG-R5IgmT-jzwoUOk8s74jwxpATG-jLEcSAJc3Z-Qy5d3oY5l3hGn0qBomwx5d2IN2-xlMwu-KfVI2vGhM9u78Pq89vTTyfv67OP7z6cHJ_Vfek113ZgXdN0Q89aISnrmJJUARUKWKPQcissl9ixtWgH2gOiMIa1wBXtKZhB8cPq9V73IoYvc2lETy71OI7GY5iTLjKtath6vaAv_0LPwxx96U4zAZJSIcvq76iNGVE7b0OOpl9E9bEUUjZQll2oo39Q5Qw4uT54tK6830t49UfCtiw2b1NYPiT4dB9ke7CPIaWIVl9EN5m40xT0YhC9N4guBtE3BtFXJenF7WhzN-Fwl_LLEQXgeyCVkN9g_D37f2R_AsMExrM</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Park, Jung Ha</creator><creator>Kim, Ju Young</creator><creator>Choi, Jong Han</creator><creator>Park, Hye Soon</creator><creator>Shin, Hyun-Young</creator><creator>Lee, Jae Min</creator><creator>Kim, Jin-Wook</creator><creator>Ko, Hae-Jin</creator><creator>Chon, Suk</creator><creator>Kim, Bu Kyung</creator><creator>Kim, Chul Sik</creator><creator>Lim, Soo</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T2</scope><scope>7TK</scope><scope>7TS</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6018-3337</orcidid><orcidid>https://orcid.org/0000-0002-4137-1671</orcidid><orcidid>https://orcid.org/0000-0002-1269-333X</orcidid><orcidid>https://orcid.org/0000-0001-9584-0974</orcidid></search><sort><creationdate>20210401</creationdate><title>Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention</title><author>Park, Jung Ha ; Kim, Ju Young ; Choi, Jong Han ; Park, Hye Soon ; Shin, Hyun-Young ; Lee, Jae Min ; Kim, Jin-Wook ; Ko, Hae-Jin ; Chon, Suk ; Kim, Bu Kyung ; Kim, Chul Sik ; Lim, Soo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c473t-fd2b44bdc295612b2761701570247ef3f5f36eb2859d1c0ee5aa290371c10ad73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>692/163/2743/393</topic><topic>692/699/1702/393</topic><topic>692/699/2743/2037</topic><topic>692/699/2743/393</topic><topic>Adult</topic><topic>Adverse events</topic><topic>Antidiabetics</topic><topic>Blood Pressure</topic><topic>Body Mass Index</topic><topic>Body size</topic><topic>Body Weight</topic><topic>Body weight loss</topic><topic>Diabetes mellitus</topic><topic>Diarrhea</topic><topic>Drug therapy</topic><topic>Epidemiology</topic><topic>Exercise</topic><topic>Female</topic><topic>Health Promotion and Disease Prevention</topic><topic>Heart Disease Risk Factors</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Life Style</topic><topic>Liraglutide</topic><topic>Liraglutide - therapeutic use</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolic Diseases</topic><topic>Middle Aged</topic><topic>Nausea</topic><topic>Obesity</topic><topic>Obesity - therapy</topic><topic>Patient outcomes</topic><topic>Public Health</topic><topic>Republic of Korea</topic><topic>Vomiting</topic><topic>Weight Loss</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Park, Jung Ha</creatorcontrib><creatorcontrib>Kim, Ju Young</creatorcontrib><creatorcontrib>Choi, Jong Han</creatorcontrib><creatorcontrib>Park, Hye Soon</creatorcontrib><creatorcontrib>Shin, Hyun-Young</creatorcontrib><creatorcontrib>Lee, Jae Min</creatorcontrib><creatorcontrib>Kim, Jin-Wook</creatorcontrib><creatorcontrib>Ko, Hae-Jin</creatorcontrib><creatorcontrib>Chon, Suk</creatorcontrib><creatorcontrib>Kim, Bu Kyung</creatorcontrib><creatorcontrib>Kim, Chul Sik</creatorcontrib><creatorcontrib>Lim, Soo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Agriculture Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>International Journal of Obesity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Park, Jung Ha</au><au>Kim, Ju Young</au><au>Choi, Jong Han</au><au>Park, Hye Soon</au><au>Shin, Hyun-Young</au><au>Lee, Jae Min</au><au>Kim, Jin-Wook</au><au>Ko, Hae-Jin</au><au>Chon, Suk</au><au>Kim, Bu Kyung</au><au>Kim, Chul Sik</au><au>Lim, Soo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention</atitle><jtitle>International Journal of Obesity</jtitle><stitle>Int J Obes</stitle><addtitle>Int J Obes (Lond)</addtitle><date>2021-04-01</date><risdate>2021</risdate><volume>45</volume><issue>4</issue><spage>776</spage><epage>786</epage><pages>776-786</pages><issn>0307-0565</issn><eissn>1476-5497</eissn><abstract>Objective
We investigated the efficacy and safety of liraglutide 3 mg daily in combination with diet and exercise 2, 4, and 6 months after initiation in real-world settings in Korea.
Methods
People first using liraglutide starting in 2018 were recruited from ten sites in Korea. Body weight and body mass index (BMI) were measured after 2, 4, and 6 months and compared with baseline values.
Results
The full cohort comprised 769 participants: 672 in the 2-month group, 427 in the 4-month group, and 219 in the 6-month group. The baseline mean ± standard deviation of BMI and body weight were 32.2 ± 5.1 kg/m
2
, and 87.5 ± 18.8 kg, respectively. Body weight and BMI decreased after initiation of liraglutide treatment: −2.94 kg and −1.08 kg/m
2
at 2 months; −4.23 kg and −1.55 kg/m
2
at 4 months, and −5.14 kg and −1.89 kg/m
2
at 6 months (all
P
< 0.001). In the 6-month cohort, 52.5% and 18.3% of subjects lost ≥5% and ≥10% of body weight, respectively. After 6 months, systolic and diastolic blood pressure decreased significantly by 3.90 and 1.93 mmHg, respectively. In those with diabetes mellitus, HbA1c and fasting glucose levels decreased significantly by 1.14% and 27.8 mg/dl, respectively. Among all participants, 27.6% experienced adverse effects, including nausea (20.8%), vomiting (5.2%), diarrhoea (2.5%), and skin rash (3.6%). Documented reasons for discontinuation of treatment were lack of effect (4.4%), adverse events (4.3%), and high cost (3.1%).
Conclusions
In real-world settings in Korea, daily treatment with liraglutide 3 mg was associated with clinically meaningful weight loss without serious adverse events.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>33473176</pmid><doi>10.1038/s41366-021-00739-z</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-6018-3337</orcidid><orcidid>https://orcid.org/0000-0002-4137-1671</orcidid><orcidid>https://orcid.org/0000-0002-1269-333X</orcidid><orcidid>https://orcid.org/0000-0001-9584-0974</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0307-0565 |
| ispartof | International Journal of Obesity, 2021-04, Vol.45 (4), p.776-786 |
| issn | 0307-0565 1476-5497 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2479742887 |
| source | MEDLINE; Springer Journals; Nature |
| subjects | 692/163/2743/393 692/699/1702/393 692/699/2743/2037 692/699/2743/393 Adult Adverse events Antidiabetics Blood Pressure Body Mass Index Body size Body Weight Body weight loss Diabetes mellitus Diarrhea Drug therapy Epidemiology Exercise Female Health Promotion and Disease Prevention Heart Disease Risk Factors Humans Internal Medicine Life Style Liraglutide Liraglutide - therapeutic use Male Medicine Medicine & Public Health Metabolic Diseases Middle Aged Nausea Obesity Obesity - therapy Patient outcomes Public Health Republic of Korea Vomiting Weight Loss |
| title | Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T21%3A23%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20of%20liraglutide%203%E2%80%89mg%20for%20the%20treatment%20of%20obesity%20in%20a%20real-world%20setting%20without%20intensive%20lifestyle%20intervention&rft.jtitle=International%20Journal%20of%20Obesity&rft.au=Park,%20Jung%20Ha&rft.date=2021-04-01&rft.volume=45&rft.issue=4&rft.spage=776&rft.epage=786&rft.pages=776-786&rft.issn=0307-0565&rft.eissn=1476-5497&rft_id=info:doi/10.1038/s41366-021-00739-z&rft_dat=%3Cgale_proqu%3EA656640502%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2506115641&rft_id=info:pmid/33473176&rft_galeid=A656640502&rfr_iscdi=true |